Drugs / Traditional Chinese Medicine Formulation
Traditional Chinese Medicine Formulation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04403529 | May 2020 → May 2024 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT07396701 Comparator | Feb 2026 → Jun 2028 expected | pneumonia | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05672498 Comparator | Jan → Apr 2023 | COVID-19 | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Traditional Chinese Medicine Formulation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07396701 ↗ |
| Known as | "prescription for breast cancer" Traditional Chinese Medicine formulation | “The "prescription for breast cancer" Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in...” NCT04403529 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Traditional Chinese Medicine” NCT04403529 ↗ |
| Route | Oral | “60 days of oral Traditional Chinese Medicine” NCT04403529 ↗ |